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Breast malignant neoplastic disease is one of the most complex diseases, as it is a
multifactorial disease in which virtually all the targets are instantly or indirectly inter-reliant
on each other. Cisplatin (CIS), an inorganic antineoplastic agent is widely utilized in the
treatment of various solid tumors including breast cancer. Despite everything, its clinical
use is limited, due to ototoxicity, peripheral neuropathy, and nephrotoxicity. The present
work was directed to assess the combined result of curcumin (CUR) and CIS in 7,
12-dimethyl benz[a]anthracene (DMBA) induced breast cancer in rats and the prevention
of nephrotoxicity induced by the latter. CIS-induced nephrotoxicity was assessed by
change in body weight, kidney weight, altered levels of BUN, creatinine, TNF-α, IL-6,
IL-8, IL-10, and histopathology of the kidney. Anticancer activity was assessed by
measurement of tumor weight, tumor volume, % tumor inhibition, levels of PPAR-γ, and
BDNF in mammary tumors and histopathology of mammary tumors. CUR pre-treatment
mitigated nephrotoxicity by reducing the inflammatory markers (TNF-α, IL-6, and IL-8; p
< 0.001). Further, it reduced mammary cancer via increasing the expression of PPAR-γ
(p < 0.001) and decreasing the expression of BDNF (p < 0.001) in mammary tumors. It
also reduced tumor volume, further postulating that CUR might adjunct the anticancer
activity of the CIS. To the best of our knowledge, this is the first report, which showed
that CUR ameliorated CIS-induced nephrotoxicity and improved its anticancer activity in
DMBA induced breast cancer in female Sprague-Dawley rats.
Keywords: brain-derived neurotrophic factor, breast cancer, cisplatin, curcumin, nephrotoxicity, peroxisome
proliferator activated receptor-γ
INTRODUCTION
The prevalence of breast carcinoma is increasing by leaps and bounds especially in the developing
countries (Kumar et al., 2013b). It is the most prevalent form of cancer in developed countries and
the secondmost commonly diagnosedmalignancy in the third world countries (Kumar et al., 2015).
Increased incidence of breast cancer in females; especially the younger ones, demands prompts,
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and intense interventions making the therapy more effective and
less toxic (Kumar et al., 2013a; Jamdade et al., 2015b).
Cisplatin (CIS), a frequently employed broad-spectrum
antineoplastic agent, remains to be a preferred treatment
modality for various malignancies despite ototoxicity, peripheral
neuropathy, and nephrotoxicity (Mundhe et al., 2015; Jamdade
et al., 2015a). The complex spectrum of CIS nephrotoxicity
includes DNA damage, tubular toxicity, and inflammation
(Kumar et al., 2013c). The inflammation plays a central
pathophysiological role in CIS associated nephrotoxicity, as CIS
injection induces a cascade of inflammatory responses in the
kidney through the release of several cytokines (TNF-α, IL-
1β etc.) and chemokines [MCP-1, macrophage inflammatory
protein (MIP)-2 etc.]. TNF-α plays a significant role in the
production of other inflammatory cytokines and chemokines
and is a chief wrongdoer of the CIS-induced inflammatory renal
injury (Deng et al., 2001; Ramesh and Reeves, 2002; Kumar et al.,
2013c). Times and again, umpteen theories have been proposed
for prevention of its nephrotoxicity but of little/no avail (Ueki
et al., 2013).
Curcumin (CUR), 1,7-bis(4-hydroxy 3-methoxy phenyl)-1,6-
heptadione-3,5-dione or diferuloylmethane is a natural yellow-
colored polyphenol derived from the perennial herb Curcuma
longa, commonly called turmeric. The three major ingredients
of commercial CUR are: curcumin (77%), demethoxycurcumin
(17%), and bisdemethoxycurcumin (3%) together referred to
as curcuminoids (Aggarwal et al., 2003; Agrawal and Mishra,
2010). The different biological and pharmacological actions
of CUR e.g., anti-inflammatory, antioxidant, anti-ischemic,
antibacterial, antifungal, and anticancer are due to different
methoxy substitutions in the chemical structure of these
compounds (Nabavi et al., 2014). Curcumin (CUR) can diminish
renal damage by modulating organic anion export markers,
drug resistance markers, through suppression of mTOR effector
pathways or inhibition of NF-κB, TNF-α, IL-6 etc. (Jobin et al.,
1999; Kuhad et al., 2007; Ueki et al., 2013). The combination of
CUR and α-tocopherol is renoprotective by inhibiting of NADPH
oxidase (Palipoch et al., 2013). Former studies have urged that
usage of rosiglitazone and CUR (anti-inflammatory agents) is
safe and one of the key approaches to attenuate CIS-induced
renotoxicity (Ueki et al., 2013; Kumar et al., 2013c).
Peroxisome proliferator-activated receptor (PPAR)-γ
belongs to the nuclear receptor superfamily of ligand-activated
transcription factors. It heterodimerizes with the retinoid
X receptor (RXR) and binds to the PPAR response element
(PPRE; Yamaguchi et al., 2006). The ligands for PPAR-γ include
synthetic agents like rosiglitazone, pioglitazone, and natural
compound such as CUR (Jacob et al., 2007). PPAR-γ is mainly
linked to differentiation of adipose tissue but it has likewise been
reported to control the development, differentiation, and gene
expression of different cancer cells (Barak et al., 1999; Gupta and
Dubois, 2002). The agents like CUR can sensitize cancer cells to
the cytotoxic action of chemotherapy, thereby cutting down the
dosage and hence, the associated toxicities. Curcumin augments
the anticancer effects of CIS and exerts its own anticancer activity
by blocking transformation, tumor initiation, tumor promotion,
invasion, angiogenesis, and metastasis (Aggarwal et al., 2003).
Brain-derived neurotrophic factor (BDNF) is a member of the
nerve growth factor family and plays an important role in the
survival and growth of neurones. Tropomyosin-related kinase B
(TrkB) is the primary receptor of BDNF, which functions as a
tyrosine kinase (Descamps et al., 2001; Blasco-Gutierrez et al.,
2007). BDNF has been associated with several human neoplasms
including ovarian, lung, prostate, hepatocellular, pancreatic, head
and neck squamous cell carcinomas, and breast cancer (Patani
et al., 2011). Interestingly, this nerve growth factor (NGF) has
been demonstrated to stimulate proliferation, angiogenesis, and
behaves as an anti-apoptotic factor in human breast cancer (Dolle
et al., 2004; Adriaenssens et al., 2008).
Based upon the above facts, we hypothesize that pre-treatment
of CUR along with CIS may diminish its nephrotoxicity and
synergize its anticancer activity in chemically induced breast
cancer in female Sprague-Dawley rats. In the current study,
we examined the mechanism underlying the effect of CUR on
CIS-induced renal damage and its antineoplastic efficacy.
METHODS
Materials
DMBA, CIS, and CUR were purchased from Sigma (St. Louis,
MO, USA). Interleukin (IL)-6, IL-8, IL-10, and tumor necrosis
factor (TNF)-α enzyme-linked immunosorbent assay (ELISA)
kits were purchased from Invitrogen (Invitrogen Corporation,
Frederick, USA). The BDNF ELISA kit was purchased from
Abnova (Abnova, Taipei, Taiwan). CIS solution was prepared
in normal saline and CUR was suspended in carboxymethyl
cellulose (CMC). The drug/molecular target nomenclature
conforms to the BJP’s Concise Guide to Pharmacology
(Alexander et al., 2015). All the solutions were prepared
fresh before each experiment.
Animals
The experiments were performed on female Sprague-Dawley rats
(National Institute of Nutrition, Hyderabad, India) maintained
at the Animal House in the Department of Pharmacology,
Guwahati Medical College and Hospital (GMCH) Assam. The
rats were put up and maintained at temperature and humidity
levels as defined in the Guide for the Care and Use of Laboratory
Animals, Public Health Service Policy on Humane Care and
Use of Laboratory Animals. The work was sanctioned by
the GMCH Institutional Animal Ethics Committee (approval
number: MC/32/2013/2) and all experiments were taken in
accordance with the Guide for the Care and Use of Laboratory
Animals, Public Health Service Policy on Humane Care and
Use of Laboratory Animals, and Animal Welfare Act. All
studies involving animals are reported in accordance with the
ARRIVE guidelines for reporting experiments involving animals
(McGrath et al., 2010). Standard animal feed (Pranaw Agro
Industries, New Delhi) and water were provided to the animals
ad libitum. The chemically induced mammary tumor animals
were examined daily for signs of distress or bother. Extra care
was given at 12th week when the tumors were developed.
The overall clinical status, including appearance, attitude, body
temperature, presence of persistence anorexia, and/or labored
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FIGURE 1 | Timeline of the study.
respiration, behavioral and physiological reactions of every
tumor bearing animals were routinely monitored. The food
and water intake, body weight, and tumor volume were
assessed frequently. The animals were checked for ulceration or
distension of tumors. Rats which were expected soon to become
moribund were anaesthetized and killed humanely by cervical
dislocation.
Tumor Induction
Female Sprague-Dawley rats at the age of 8 weeks weighing 160–
180 g were gavaged with DMBA (60 mg/kg body weight), a dose
sufficient to make 100% tumor incidence in the control group
over the course of the study (Whitsett et al., 2006; Tikoo et al.,
2009a). The DMBA was dissolved in olive oil in a stock solution
of 30 mg/ml.
Experimental Design
Initially, 40 animals were administered with DMBA, out of
which 5 animals died within 5 weeks of DMBA administration.
Further, 2 more animals died during the tumor development
period; yet, the death was imputed to the mammary tumors.
Animals were palpated twice a week, starting 5 weeks after DMBA
administration in order to tape the visual aspect, position and size
of tumors. The mammary tumors reached measurable level after
12 weeks of DMBA administration. One animal was not included
while grouping since it was harboring disproportionately grown
mammary tumors. The animals were sacrificed when the tumor
diameter reached 3 cm, animals became moribund (Exclusion
criteria), or after the culmination of the experimentation. After 12
weeks, DMBA treated rats were grouped into 4 different groups
on the basis of their tumor volume. DMBA treated rats received
normal saline (Group I). Breast cancer-induced rats were treated
with CUR (120 mg/kg) suspended in 0.25% w/v CMC through
oral gavage for 5 days (Group II). Breast cancer-induced rats
were treated with CIS (7.5 mg/kg) dissolved in normal saline
(0.9% w/v) by intraperitoneal route (Group III). Breast cancer-
induced rats were treated with CUR (120 mg/kg) suspended in
0.25% w/v CMC for 5 days followed by a single dose of CIS
dissolved in normal saline (0.9% w/v) by intraperitoneal route
on the 5th day was assigned as Group IV (Figure 1). Rats were
weighed prior to the injection and 4 days after CIS treatment.
Blood samples were collected on the 5th day from the rat tail
veins under light ether anesthesia in heparinized centrifuge tubes
and plasma was separated by centrifugation at 2,300 g. Plasma
was stored at −80◦C until assayed. The study design and animal
ethics conform to the recent guidance on experimental design
and analysis (Curtis et al., 2015). All the animals were maintained
on a standard diet and water during the entire period of
study.
Measurement of Tumor Volume and %
Tumor Inhibition
The measurements were done for visible tumors; two diameters
i.e., shortest and longest diameter of the tumors was measured.
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The volume of the tumor was calculated as pi/6 (a)2∗(b), where
a is the smallest and b is the longest length of the tumor.
Percentage tumor inhibition was calculated by taking tumor
volume of day 0 of all the groups as 100% and then percentage
inhibition was calculated by comparing 0th day tumor volume
with 3rd, 6th, and 9th day tumor volumes of the respective
groups.
Group Animal
number
Shortest
diameter (a)
Longest diameter (b) Formula (= pi/6∗a2∗b) Tumor Volume (mm3)
Breast Cancer Control
(BCC)
1 0.33 cm 0.44 cm = 3.14/6∗0.332∗0.44 24.92
= 0.52∗0.1089∗0.44
= 0.02492 cm3
= 0.02492∗1000 mm3
= 24.92 mm3
Estimation of Blood Urea Nitrogen,
Creatinine, and Plasma Albumin
Blood samples were collected in heparinized centrifuge tubes and
immediately centrifuged at 2,300 g for the separation of plasma
and were stored at −80◦C until assayed. The plasma was used
for the estimation of blood urea nitrogen (BUN), creatinine and
albumin as described previously (Kumar et al., 2013c).
Measurement of Inflammatory Markers
and BDNF Level
The levels of TNF-α, IL-6, IL-8, and IL-10 in breast cancer tissue
and BDNF in plasma were determined by using ELISA kits,
according to the manufacturer’s instructions. In all the cases, a
standard curve was constructed from the criteria provided by the
producer.
Histopathology of Kidney and Mammary
Tumor
Histopathology of the kidney and the mammary tumor was
performed as described previously (Mundhe et al., 2015; Jamdade
et al., 2015a). Briefly, for light microscopy, autopsy samples were
taken from the kidney and the mammary tumor of rats from
different groups and fixed in 10% formal saline for 24 h. The
washing was made out with distilled water, then serial dilutions
of alcohol (methyl, ethyl, and absolute ethyl) were used for drying
up. Specimens were cleared in xylene and embedded in paraffin
at 56◦C in hot air oven for 24 h. Paraffin beeswax tissue blocks
were prepared for sectioning at a thickness of 4 µm by sledge
microtome. The obtained tissue sections were collected on glass
slides, deparaffinized, stained with haematoxylin and eosin stain
for routine examination then examination was done through the
light electric microscope.
Protein Isolation and Western Blotting
Mammary gland tumor (∼50 mg) was homogenized with
ice-cold 500 ml mixture of radioimmunoprecipitation assay
(RIPA) buffer and protease inhibitor cocktail. The homogenate
was centrifuged (13,000 g, 20 min, 4◦C) and the supernatant
containing protein was collected and stored at −80◦C. Protein
concentration in the supernatant was determined using the
method of Lowry et al. (1951). For western blot analysis, SDS-
PAGE was carried out utilizing a vertical midi gel system
(GeneiTM, Merck). Briefly, 10–20 µg of protein sample was
mixed with the appropriate measure of a freshly prepared Laemli
buffer. The mix was heated at 70◦C for 10min on a water bath;
loaded onto the polyacrylamide gel and run at 100 V for around
120min. Protein was transferred onto a nitrocellulose membrane
using semi-dry blotter (Merck Millipore) at 90 mA for 1 h.
Immunoblot analysis was performed by using Western DotTM
625 Goat Anti-Rabbit Western Blot Kit using the supplier’s
manual. Following primary antibodies were used: monoclonal
anti-β-actin antibody, 1:2,000 (Sigma-Aldrich); an antibody to
BDNF (rabbit 1:1,000, Santa Cruz, CA) and antibody to PPAR-
γ (rabbit 1:2000, Santa Cruz, CA). The membrane was imaged
using a UV transilluminator (Biostep UST-20M-8E & ArgusX1).
Quantitative analysis of the picture was done using ImageJ
software. The results were normalized with respect to β-actin.
Statistical Analysis
Data are represented as means ± S.E.M. and were analyzed
by Prism 5.0 statistical program (GraphPad Software Inc., San
Diego, CA, USA). Comparisons between experimental groups
were performed using one-way ANOVA followed by Tukey’s
post-hoc test. Differences were considered significant if the p-
value was less than 0.05.
RESULTS
Combined Effect of CUR and CIS on Body
Weight, Kidney Weight, and Tumor Weight
Body weight, kidney weight and tumor weight were assessed at
the end of the study. As shown inTable 1, CIS treated rats showed
a significant loss in body weight when compared with mammary
cancer control rats. There was no significant change in the body
weight of curcumin treated rats when compared with mammary
cancer control rats. CUR pre-treatment for 5 days in CIS treated
rats showed a significant gain in body weight (p < 0.001)
as compared to CIS treated mammary cancer rats. Moreover,
substantial growth in kidney weight (p < 0.001) was observed
in CIS treated rats, as compared to mammary cancer control
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TABLE 1 | Effect of curcumin plus cisplatin treatment on body weight, kidney weight, BUN, creatinine, and albumin.
Body weight (g) Kidney weight (g) BUN (mg/dl) Creatinine (mg/dl) Albumin (g/dl)
BCC 238 ± 2.2 0.601 ± 0.02 21 ± 3.53 1.0 ± 0.12 3.99 ± 0.12
CUR 248 ± 3.1 0.610 ± 0.03 23 ± 2.85 1.03 ± 0.05 3.91 ± 0.09
CIS 218 ± 2.6***a 0.798 ± 0.02***a 149 ± 8.20***a 3.07 ± 0.35***a 2.23 ± 0.14***a
CUR + CIS 235 ± 2.1***b 0.641 ± 0.01***b 52 ± 5.41***b 1.3 ± 0.23***b 3.74 ± 0.20***b
All the values were expressed as mean ± SEM (n = 8). ***P < 0.001. avs. breast cancer control, bvs. cisplatin. Where BCC is breast cancer control, CUR is curcumin, CIS is cisplatin,
and CUR + CIS is pre-treatment of curcumin (120mg/kg) for 5 days, followed by single dose of cisplatin (7.5mg/kg) on the 5th day.
rats. CUR pre-treatment for 5 days restored the kidney weight
(p < 0.001) to mammary cancer control rats’ kidney weight.
Mammary cancer control rats presented maximum tumor weight
as compared to drug treated groups. Treated animals showed
a substantial decrease in the tumor weights as compared to
cancer control animals. Furthermore, CUR plus CIS combination
treated rats exhibited a significant decrease (p < 0.001) in the
tumor weight as compared to CUR (p < 0.001) and CIS (p <
0.05) alone treated mammary cancer rats (Figure 2).
Combined Effect of CUR and CIS on Renal
Function
Treatment of CIS showed a significant increase in the level
of BUN (p < 0.001) when compared with mammary cancer
control rats. CUR pre-treatment for 5 days followed by
CIS treatment showed significant reduction in BUN (p <
0.001) level, as compared to CIS alone treated mammary
cancer rats (Table 1). Treatment with CIS produced significant
elevations of creatinine level (p < 0.001) when compared
with mammary cancer control rats. Pre-treatment with CUR
for 5 days before CIS treatment showed significant reduction
of creatinine level (p < 0.01), as compared to CIS treated
rats (Table 1). Furthermore, treatment of CIS significantly
decreased plasma albumin levels (p < 0.001) as compared to
cancer control animals. CIS injection damages the glomeruli
by an inflammatory mechanism which results in the increased
permeability of the glomerulus and podocytes (highly specialized
cells) and this is responsible for the reduced level of albumin
in the blood. Pre-treatment with CUR for 5 days prior
to CIS treatment showed significant elevation of plasma
albumin levels (p < 0.001), as compared to CIS treated breast
cancer rats (Table 1). CUR alone treated rats exhibited no
substantial change in BUN, creatinine, and albumin levels.
These observations demonstrated that CUR pre-treatment
was efficacious in reducing CIS-induced kidney injury in
DMBA induced mammary carcinoma in female Sprague-Dawley
rats.
Combined Effect of CUR and CIS on
Inflammatory Markers in Renal Tissue in
Mammary Cancer
Inflammatory markers were measured in the renal tissue at the
end of the study in all the groups. Cisplatin-treated rats exhibited
significantly increased levels of TNF-α (p < 0.001), IL-6 (p <
0.01), and IL-8 (p < 0.001) whereas, significantly decreased the
FIGURE 2 | Combined effect of curcumin and cisplatin on tumor weight
in breast cancer rats. All the values were expressed as mean ± SEM
(n = 8). *P < 0.05, ***P < 0.001. a vs. breast cancer control, b vs. cisplatin,
and c vs. curcumin. Where BCC is breast cancer control, CUR is curcumin,
CIS is cisplatin, and CUR + CIS is pre-treatment of curcumin (120mg/kg) for 5
days, followed by single dose of cisplatin (7.5mg/kg) on the 5th day.
level of IL-10 (p < 0.01) on the 5th day when compared with
breast cancer control rats. However, curcumin pre-treatment for
5 days in cisplatin-treated rats significantly reduced the levels of
TNF-α (p < 0.001), IL-6 (p < 0.01), and IL-8 (p < 0.05) whereas
significantly improved the level of IL-10 (p< 0.001) as compared
to cisplatin-treated breast cancer rats (Figure 3).
CUR Improves Antitumor Activity of CIS in
Mammary Cancer
Tumor Volume
Figure 4 shows the tumor volumes of CUR, CIS, CUR plus CIS,
and mammary cancer control rats. There was a considerable
increase in tumor volume of mammary cancer control rats
when compared with the drug treated rats, viz. CIS alone, CUR
alone and CUR plus CIS treated rats. CIS (p < 0.05), CUR
(p < 0.05), and CUR pre-treated (p < 0.01) rats showed a
significant reduction in their tumor volumes when compared
withmammary cancer control rats. However, CUR pre-treatment
for 5 days followed by a single dose of CIS treated rats exhibited a
maximum reduction (p< 0.01) in tumor volume when compared
with CUR and CIS alone treated rats.
% Tumor Inhibition
Table 2, shows the % tumor inhibition of treated (CUR, CIS,
and CUR plus CIS) and mammary cancer control rats. There
was a considerable tumor progression in breast cancer control
rats as compared to CUR, CIS, and CUR plus CIS treated rats.
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FIGURE 3 | Effect of curcumin plus cisplatin treatment on inflammatory markers in breast cancer (A–D). All the values were expressed as mean ± SEM
(n = 8). *P < 0.05, **P < 0.01, ***P < 0.001. a vs. breast cancer control, b vs. cisplatin. Where BCC is breast cancer control, CUR is curcumin, CIS is cisplatin, and
CUR + CIS is pre-treatment of curcumin (120 mg/kg) for 5 days, followed by single dose of cisplatin (7.5 mg/kg) on the 5th day.
FIGURE 4 | Combined anticancer effect of curcumin pre-treatment and
cisplatin on tumor volume (mm3) in breast cancer rats. All the values
were expressed as mean ± SEM (n = 8). *P < 0.05, **P < 0.01. a vs. breast
cancer control. Where BCC is breast cancer control, CUR is curcumin, CIS is
cisplatin, and CUR + CIS is pre-treatment of curcumin (120 mg/kg) for 5 days,
followed by single dose of cisplatin (7.5 mg/kg) on the 5th day.
In drug-treated rats, the tumor did not break off totally, but a
substantial regression was recorded when compared with breast
cancer control rats. CUR treated group showed 7% reduction on
3rd day, 15% reduction on the 6th day, and 20% on the 9th day of
the tumor volume when compared with 0 day tumor volume. CIS
treated rats showed 12% reduction on the 3rd day, 18% reduction
on the 6th day, and 24% on the 9th day of the tumor volumewhen
compared with 0 day tumor volume. In event of pre-treated rats,
there was a 25% reduction on 3rd day, 43% reduction on the 6th
day, and 66% reduction on the 9th day of the tumor volume when
compared with 0 day tumor volume. From the above results, it
TABLE 2 | The combined anticancer effects of curcumin and cisplatin on
% tumor inhibition in breast cancer rats.
0th Day 3rd Day 6th Day 9th Day
BCC 100 178 (+78) 245 (+145) 292 (+192)
CUR 100 93 (−7) 85 (−15) 80 (−20)
CIS 100 88 (−12) 82 (−18) 76 (−24)
CUR + CIS 100 75 (−25) 57 (−43) 34 (−66)
Where BCC is breast cancer control, CUR is curcumin, CIS is cisplatin, and CUR + CIS
is pre-treatment of curcumin (120 mg/kg) for 5 days, followed by single dose of cisplatin
(7.5 mg/kg) on the 5th day.
was very clear that CUR pre-treatment (followed by CIS) treated
rats showed more anticancer activity when compared with CIS
and CUR alone treated rats.
Combined Effect of CUR and CIS on BDNF
Expression in Mammary Cancer Rats
The level of BDNF in mammary tumors was measured on the
5th day after the administration of CUR, CIS, and combination
of CUR with CIS. The drug treated groups displayed significant
reductions (p < 0.001) in circulating BDNF levels compared
to control rats. Moreover, the combination of CUR with CIS
showed amaximum reduction in the BDNF level when compared
with CUR (p < 0.001) and CIS (p < 0.01) alone treated
groups. Likewise, similar findings were observed in Western
Blotting for quantification of BDNF supporting ELISA results
(Figures 5, 6).
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FIGURE 5 | Effect of curcumin plus cisplatin treatment on BDNF in
breast cancer rats. All the values were expressed as mean ± SEM (n = 8).
**P < 0.01, ***P < 0.001. a vs. breast cancer control, b vs. cisplatin, and c vs.
curcumin. Where BCC is breast cancer control, CUR is curcumin, CIS is
cisplatin, and CUR + CIS is pre-treatment of curcumin (120mg/kg) for 5 days,
followed by single dose of cisplatin (7.5 mg/kg) on the 5th day.
Combined Effect of CUR and CIS On
PPAR-γ Expression in Mammary Cancer
Rats
In this study, mammary cancer control rats showed low PPAR-
γ expression, when compared with all drug-treated groups.
However, we found higher PPAR-γ expression in CUR (p <
0.001) and CIS (p < 0.001) treated rats as compared to cancer
control rats. Moreover, CUR pre-treatment for 5 days in CIS
treated rats showed maximum expression of PPAR-γ when
compared with CUR (p < 0.001) and CIS (p < 0.001) alone
treated rats (Figure 6).
Combined Effect of CUR and CIS on Renal
Histology in Mammary Cancer Rats
Inmammary cancer control rats, we observed intact renal tubules
and glomeruli (Figure 7A). In addition, uniform tubules with a
single layer of epithelium lining were observed in renal cortex in
mammary cancer control rats. CIS treated rats revealed necrosis,
protein cast, vacuolation, and desquamation of epithelial cells
in renal tubules (Figure 7C). However, CUR pre-treatment for
5 days in CIS treated rats significantly protected the kidney
architecture as compared to CIS treated rats (Figure 7D). CUR
alone treated rats had no effect on renal histology (Figure 7B).
Figure 7E represents the quantification of kidney histopathology.
Combined Effect of CUR and CIS on
Mammary Tumor Histology
Mammary cancer control rats showed nuclear pleomorphism,
abundant mitotic figures, and atypical mitotic figures
(Figure 8A). CUR treated rats showed a low grade of
differentiation which was demonstrated by giant multinucleated
cells (Figure 8B). Decreased cell density and a higher level of
fibrosis were observed in CIS treated animals (Figure 8C).
However, CUR plus CIS treatment decreased nuclear
pleomorphism along with a decrease in mitotic figures as well as
atypical mitotic figures (Figure 8D), suggesting a combination
of CUR plus CIS prevents tumor progression significantly.
Figure 8E represents the quantification of mammary tumor
histopathology.
DISCUSSION
The observation of the present study is that activation of PPAR-
γ and inactivation of BDNF in mammary tissue inhibited the
growth of breast cancer in rats. The cumulative treatment of
CUR plus CIS augmented the expression of PPAR-γ while
lessening the expression of BDNF in mammary tumors. The
subsequent finding of this work is that CUR pre-treatment
ablated the cisplatin-induced nephrotoxicity in breast cancer rats.
CIS injection to tumor bearing rats resulted in kidney toxicity
by means of inflammatory pathways. Mechanistically, CUR pre-
treatment ameliorated the cisplatin-induced nephrotoxicity by
inhibiting the pro-inflammatory cytokines like TNF-α, IL-6,
IL-8, and augmenting anti-inflammatory cytokine (IL-10) in
mammary tumor bearing rats. However, CUR did not affect the
inflammatory responses in other groups (BCC, CUR).
In this work, the CIS injection significantly elevated renal
pro-inflammatory cytokines in breast cancer rats. Conversely,
CUR pre-treatment significantly reduced the pro-inflammatory
cytokines and improved the anti-inflammatory cytokine in
mammary tumor bearing rats. Our study outcomes paralleled
with the findings of Kuhad and his colleagues, in which they
have proved the renoprotective effect of curcumin in cisplatin-
induced nephrotoxicity. They have studied low dose of CUR
with different pre and post-treatment time schedule to check
the renoprotective effect of CUR in CIS-induced nephrotoxicity
through anti-inflammatory and antioxidant mechanisms (Kuhad
et al., 2007). In the present work, we have used higher doses of
curcumin and found that it safely and effectively suppressed CIS-
induced renal inflammation in rats; subjects treated with CUR
alone showed no specific side-effects or toxicity. Moreover, the
effects of the inflammatory parameters were in full accord with
the histopathological observations of this field.
The exact mechanisms underlying the suppression of
nephrotoxicity by CUR are not fully revealed. The structure
of CUR is comprised of a number of functional groups.
The two aromatic phenol rings (rings A and B) are linked
by two sets of α, β-unsaturated carbonyl groups that can
react with glutathione and other nucleophiles. The 2 aryl
methoxyl groups at the ortho position, the hydroxyl moiety
as well as the conjugated β-diketone moieties of curcumin,
which are conjugated, are other pharmacologically important
structural features (Nabavi et al., 2014). The α, β-unsaturated
diketone structural moieties of curcumin is responsible for
heme oxygenase-1 and NFκB suppression (Rajasekaran, 2011).
Sandur and his colleagues also reported that the α, β-unsaturated
diketone moiety, in conjugation with phenolic rings, has a crucial
role in NFκB activity (Sandur et al., 2007). Our results are
in accordance with previous studies which reported that CUR
down-regulates the transcription factor NFκB and suppresses
various inflammatory mediators (Jobin et al., 1999; Kim et al.,
2005). Ueki and colleagues have shown that CUR enhances
CIS-induced nephrotoxicity by inhibiting renal inflammation
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FIGURE 6 | Western blots of PPAR-γ and BDNF in mammary tumors. Western blots of PPAR-γ and BDNF levels in mammary tumors after combined treatment
of curcumin and cisplatin in breast cancer rats. Where lane a is breast cancer control, b is curcumin, c is cisplatin, and d is Curcumin + Cisplatin. Results were
normalized with respect to actin. Similar results were obtained in three independent set of experiments. All values were expressed as mean ± SEM (n = 3). *P < 0.05,
**P < 0.01, ***P < 0.001; a vs. breast cancer control & b vs. cisplatin.
in mice (Ueki et al., 2013). Tikoo and colleagues have shown
that anti-inflammatory agents like rosiglitazone could prevent
the CIS-induced nephrotoxicity (Tikoo et al., 2009b). In this
study, we did not examine whether CUR inhibits NFκB activation
or not. Further studies may be proposed to assess the effects
of CUR administration on NFκB activation in CIS-induced
nephrotoxicity in mammary gland cancer rats.
Side by side, we discovered that the combination of CUR
sensitizes tumor cells to CIS. The compounding combination
of the CUR with CIS shows a maximum decrease in the
percentage tumor inhibition on 6th and 9th days as compared
to treatment with CIS or CUR alone. The enhanced efficacy of
the combination can either be due to the different mechanism
of these drugs (improved expression of PPAR-γ and reduced
expression of BDNF) or the chemosensitizing effect of CUR.
On that point are increasing evidence demonstrating that
pharmacological activation of PPAR-γ results in anticancer
activity in experimental models of breast cancer (Rubin et al.,
2000; Qin et al., 2003). The CUR has been shown to protect
against chemically induced breast cancer (Kumar et al., 2015).
Still, it is unclear whether CUR protects from breast cancer
by activation of PPAR-γ or not. Present data have indicated
a significant gain in both aspect and action of PPAR-γ in the
breast cancer tissue by pre-treatment of CUR, suggesting an
agonistic effect of CUR on PPAR-γ. Similarly, in our earlier study,
we had disclosed that PPAR-γ agonist, rosiglitazone, amplified
PPAR-γ expression in DMBA induced breast cancer (Tikoo et al.,
2009b). Consistent with the previous work, the present data
demonstrated that activation of the PPAR-γ by curcumin was
crucial for all facets of curcumin’s anticancer activity in rats.
In this study, we observed that CUR pre-treatment for 5 days
in CIS treated rats increased the PPAR-γ expression in mammary
tumors and hence highest anticancer activity amongst the entire
study drug-treated groups and this may be possibly responsible
for the decreased proliferation and enhanced apoptosis of
mammary cancer cells. Moreover, only CUR treated rats showed
high expression of PPAR-γ when compared with CIS treated
groups. This difference was attributed to the agonistic action as
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FIGURE 7 | Histopathological changes in the kidney after combined treatment of curcumin and cisplatin in breast cancer rats. Transverse section of
cancer control rat kidney (A), kidney after treatment with curcumin (B), cisplatin-treated (C), and pre-treatment with curcumin (D). Sections were stained with Mayer’s
hematoxylin counterstained with eosin and observed under magnification of 40X. Quantitative analysis of kidney histopathology (E) where; control rat kidney (A),
curcumin treated kidney (B), cisplatin-treated kidney (C), and curcumin treated kidney (D). ++++, Very severe; +++, Severe; ++, Moderate; +, Mild; –, None.
well as 5 doses of CUR as compared to a single dose of CIS and no
agonistic action. CUR and CIS treated rats exhibited a maximum
reduction in tumor mass and substantial improvement in tumor
morphology, further strengthening the above resolution. The
finding of this study was also in hormony with our previous
study (Tikoo et al., 2009b) in which we had tried rosiglitazone
as a PPAR-γ agonist in combination with CIS as an anticancer
cancer agent in DMBA induced breast cancer in rats. In that
study, rosiglitazone ameliorated the CIS-induced renotoxicity
and in chorus synergize the anticancer cancer activity (through
the PPAR-γ pathway). The current study also indicated a good
function of PPAR-γ specific ligands in the chemoprevention of
mammary carcinogenesis.
The stimulus of resistance to apoptosis by BDNF suggests
their possible value as therapeutic targets in breast cancer,
that provide new directions for the invention of innovative
strategies based on neurotrophin inhibition. A previous study
claimed that higher level of BDNF is significantly related
to breast cancer development and its prohibition leads to
reduced tumor cell survival (Vanhecke et al., 2011). It was
Frontiers in Pharmacology | www.frontiersin.org 9 April 2017 | Volume 8 | Article 132
Kumar et al. Curcumin Mitigates Breast Cancer
FIGURE 8 | Histopathological changes were seen in mammary tumors after combined treatment of curcumin and cisplatin. (A) Breast cancer control
group, (B) mammary tumor after treatment with curcumin: pronounced cell pleomorphism and a low grade of differentiation are demonstrated by multinucleated giant
cells, (C) cisplatin treated mammary tumor with decreased cell density and higher level of fibrosis as sign of a therapeutic effect, (D) curcumin pre-treated mammary
tumor after 5 days. The glandular structure as an indicator for a functional differentiation noticeable. (E) Quantitative analysis of histopathological studies in mammary
tumor where, breast cancer control (A), curcumin treated mammary tumor (B), cisplatin-treated mammary tumor (C), and curcumin pretreated mammary tumor (D).
further reported that the mammary cancer specimens have
a high level of BDNF as compared to normal tissue of
human subjects (Patani et al., 2011). Likewise, in the present
work, we also noted higher levels of BDNF in breast cancer
tissue. CUR pre-treatment for 5 days followed by single
injection of CIS significantly reduced BDNF expression and
inhibited progression of mammary cancer. Interestingly, CUR
plus CIS combination presented maximum fall in BDNF
level as compared to CUR or CIS treated breast cancer
rats.
In conclusion, our data suggest that curcumin pre-treatment,
along with cisplatin, potentates the antineoplastic activity
of the CIS, as well as attenuates its renotoxicity. Thus, this
combination could lead to the development of a novel
therapeutic approach with high antineoplastic activity
and low renotoxicity. The combination of CUR and CIS
may have profound clinical implications in breast cancer
treatment, yet further studies may be advised to ensure
the utility of this permutation in different breast cancer
models.
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